This study reviews publications on the history of cancer antigen 125 (CA125), the background of its use as a marker of mesothelial cell mass, determination in peritoneal effluent, and its practical use in both the follow-up of peritoneal dialysis (PD) patients and as a marker of in vivo biocompatibility of dialysis solutions.
Design
Review article.
Results
CA125 is a high molecular weight glycoprotein. Previous studies in ascites suggested its release by mesothelial cells. In vitro studies with cultured mesothelial cells showed constitutive production, the majority of which was dependent on mesothelial cell mass. Serum CA125 is normal in PD patients, but its concentration in peritoneal dialysate suggests local release, probably from mesothelial cells. Effluent CA125 can be considered a marker of mesothelial cell mass in stable PD patients, but large amounts are found during peritonitis, due probably to necrosis of mesothelial cells. The majority of studies found no relationship between dialysate CA125 and peritoneal transport parameters. Some cross-sectional studies reported a relationship with duration of PD, but others were unable to confirm this, due probably to the large interindividual variability. Longitudinal follow-up has shown a decrease in dialysate CA125, indicating loss of mesothelial cell mass. Application of theoretically morebiocompatible PD solutions causes an increase in dialysate CA125.
Conclusions
Dialysate CA125 is a mesothelial cell mass marker. The concentration of CA125 should be determined after a standardized dwell. A single low value is not informative. A decrease with time on PD suggests loss of mesothelial cell mass. Dialysate CA125 is a marker of in vivo biocompatibility of (new) dialysis solutions. More research is necessary on the best methodology for measuring low concentrations and establishing normal values and a significant change.
BastR.C.Jr., FeeneyM., LazarusH., NadlerL.M., ColvinR.B., KnappR.C.Reactivity of a monoclonal antibody with human ovarian carcinoma.J Clin Invest1981; 68: 1331–7.
2.
KabawatS.E., BastR.C.Jr., BhanA.K., WelchW.R., KnappR.C., ColvinR.B.Tissue distribution of a coelomic epithelium related antigen recognized by the monoclonal antibody OC125.Int J Gynecol Pathol1983; 2: 275–85.
3.
BastR.C.Jr., KlugT.L., St JohnE., JenisonE., NiloffJ.M., LazarusH.A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.N Engl J Med1983; 309: 883–7.
4.
JacobsL., StabileI., BridgesJ., KemsleyP., ReynoldsC., GrudzinskasJ.Multimodal approach to screening for ovarian cancer.Lancet1988; 1: 268–71.
5.
MalkasianG.D., KnappR.C., LavinP.T., ZurawskiV.R., PodrateK.C., StanhopeR.Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: Discrimination of benign from malignant disease.Am J Obstet Gynecol1988; 159: 341–6.
6.
PatsnerB., MannW.J.The value of preoperative serum CA125 levels in patients with a pelvic mass.Am J Obstet Gynecol1988; 159: 873–6.
7.
ZurawskiV.R., OrjaseterH., AndersonA., JellumE.Elevated serum CA125 levels prior to diagnosis of ovarian neoplasia: Relevance for early detection of ovarian cancer.Int J Cancer1988; 42: 677–80.
8.
BonG.J., KenemansP., VerstraetenR., Van KampG.J., HilgersJ.Serum tumor marker immunoassays in gynecologic oncology: Establishment of reference values.Am J Obstet Gynecol1996; 174: 107–14.
9.
BullerR.E., VasilevS., DiSaiaP.J.CA 125 kinetics: A cost-effective clinical tool to evaluate trial outcomes in the 1990s.Am J Obstet Gynecol1996; 174: 1241–54.
10.
JacobsI., BastR.C.Jr.The CA125 tumor-associated antigen: A review of the literature.Hum Reprod1989; 4: 1–12.
11.
Van der BurgM.E.L., LammesF.B., VerweijJ.CA125 in ovarian cancer.Neth J Med1992; 40: 36–51.
12.
MacdonaldF., DowningR., AllumW.H.Expression of CA125 in pancreatic carcinoma and chronic pancreatitis.Br J Cancer1998; 58: 505–6.
13.
O'BrienT.J., HardinJ.W., BannonG.A., NorvisJ.S., QuirkG.Jr.CA 125 antigen in human amniotic fluid and fetal membranes.Am J Obstet Gynecol1986; 155: 50–5.
14.
O'BrienT.J., RaymondL.M., BannonG.A., FordH.D., HardartottirH., MillerF.C.New monoclonal antibodies identify the glycoprotein carrying the CA 125 epitope.Am J Obstet Gynecol1991; 165: 1857–64.
15.
DavisH.M., ZurawskiV.R., BastR.C.Jr., KlugT.L.Characterization of the CA125 antigen associated with human epithelial ovarian carcinomas.Cancer Res1986; 46: 6143–8.
16.
BarbieriR.L., NiloffJ.M., BastR.C.Jr., SchnaetzeE., KistnerR.W., KnappR.C.Elevated serum concentrations of CA125 in patients with advanced endometriosis.Fertil Steril1986; 45: 630–4.
17.
HalilaH., SteumanU.H., SeppulaM.Ovarian cancer antigen CA125 levels in pelvic inflammatory disease and pregnancy.Cancer1986; 57: 1327–9.
18.
SimsehH., KadayifciA., OkanE.High serum level of CA125 in malignant peritoneal mesothelioma.Eur J Cancer1995; 31: 129.
19.
MolinaR., FilellaX., BruixJ., MengualP., BoschJ., ColvetX.Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases.Clin Chem1991; 37: 1379–83.
20.
IsmailM., RotmenschJ., MercerL.J., BlockB.S., SaltiG.I., HoltJ.A.CA125 in peritoneal fluid from patients with nonmalignant gynecologic disorders.J Reprod Med1994; 39: 510–12.
21.
OnsrudM., ShabanaA., AustgullenR., NustadK.Comparison between soluble tumor necrosis factor receptors and CA125 in peritoneal fluids as a marker for epithelial ovarian cancer.Gynecol Oncol1995; 57: 183–7.
StylianouE., JennerL.A., DaviesM., ColesG.A., WilliamsJ.D.Isolation, culture and characterization of human peritoneal mesothelial cells.Kidney Int1990; 37: 1563–70.
24.
BetjesM.G.H., TakC.W., StruijkD.G., KredietR.T., AriszL., BeelenR.H.J.Adherence of staphylococci to plastic, mesothelial cells and mesothelial extracellular matrix.Adv Perit Dial1992; 8: 215–18.
25.
KoomenG.C.M., BetjesM.G.H., ZemelD., KredietR.T., HoekF.J.Cancer antigen 125 is locally produced in the peritoneal cavity during continuous ambulatory peritoneal dialysis.Perit Dial Int1994; 14: 132–6.
26.
VisserC.E., Brouwer–SteenbergenJ.J.E., BetjesM.G.H., KoomenG.C.M., BeelenR.H.J., KredietR.T.Cancer antigen 125: A bulk marker for the mesothelial mass in stable peritoneal dialysis patients.Nephrol Dial Transplant1995; 10: 64–9.
27.
ZeillemakerA.M., VerbrughH.A., Hoynck van PapendrechtAAGM, LeguitP.CA125 secretion by peritoneal mesothelial cells.J Clin Pathol1994; 47: 263–5.
28.
CasesA., FilellaX., MolinaR., BallestaA.M., Lopez–PedretJ., RevertL.Tumor markers in chronic renal failure and hemodialysis patients.Nephron1991; 57: 183–6.
29.
ZeferosN., DigenisG.E., ChristophorakiM., AlexopoulosI., KostakisA., GyftahiH.Tumor markers in patients undergoing hemodialysis or kidney transplantation.Nephron1991; 59: 618–20.
30.
MenzinA.W., KobrinS., PollakE., GoodmanD.B.P., RubinS.C.The effect of renal function on serum levels of CA125.Gynecol Oncol1995; 58: 375–7.
31.
PassadakisP., PanagoutsosS., ThodisE., TsivaraI., SopassiF., KartaliS.Evaluation of changes in serum and dialysate levels of cancer antigen 125 in stable continuous ambulatory peritoneal dialysis patients.Adv Perit Dial1999; 15: 40–4.
32.
LyeW.C., TambyahP., LeongS.O., LeeE.J.C.Serum tumor markers in patients on dialysis and kidney transplantation.Adv Perit Dial1994; 10: 109–11.
BastianiB., ChuH.Serum CA125 in chronic peritoneal dialysis (PD) patients: The effect of PD catheter implantation and peritonitis.J Am Soc Nephrol1993; 4(Suppl 2): 397.
35.
PannekeetM.M., ZemelD., KoomenG.C.M., StruijkD.G., KredietR.T.Dialysate markers of peritoneal tissue during peritonitis and in stable CAPD.Perit Dial Int1995; 15: 217–25.
36.
TopleyN.The host's initial response to peritoneal infection: The pivotal role of the mesothelial cell.Perit Dial Int1995; 15: 116–17.
PedersonF.B., RyttovN., DeluranP., DrugsholtC., KildebergP.Acetate versus lactate in peritoneal dialysis solutions.Nephron1985; 39: 55–8.
43.
GotloibL., ShostakA., WajsbrotV., KuschnierR.The cytochemical profile of visceral mesothelium under the influence of lactated-hyper osmolar peritoneal dialysis solutions.Nephron1995; 69: 466–71.
44.
GotloibL., WajsbrotV., ShostakA., KuschnierR.Acute and long-term changes observed in imprints of mouse mesothelium exposed to glucose enriched, lactated, buffered dialysis solutions.Nephron1995; 70: 466–77.
45.
WajsbrotV., ShostakA., GotloibL., KushnierR.Biocompatibility of a glucose-free acidic lactated solution for peritoneal dialysis evaluated by population analysis of mesothelium.Nephron1998; 79: 322–32.
46.
GotloibL., WajsbrotV., ShostakA., KushnierR.Effect of hyperosmolality upon the mesothelial monolayer exposed in vivo and in situ to a mannitol-enriched dialysis solution.Nephron1999; 81: 301–9.
47.
DobbieJ.W., ZakiM., WilsonL.Ultrastructural studies on the peritoneum with special reference to chronic ambulatory peritoneal dialysis.Scott Med J1981; 26: 213–23.
48.
Di PaoloN., SacchiG., De MiaM., GaggiottiE., CapotondoL., RossiR.Morphology of the peritoneal membrane during continuous ambulatory peritoneal dialysis.Nephron1986; 44: 204–11.
49.
GotloibL., ShostakA., Bar-SellaP., CohenR.Continuous mesothelial injury and regeneration during long term peritoneal dialysis.Perit Dial Bull1987; 7: 148–55.
50.
DobbieJ.W.Morphology of the peritoneum in CAPD.Blood Purif1989; 7: 74–85.
DobbieJ.W., LloydJ.K., GallC.A.Categorization of ultra-structural changes in peritoneal mesothelium, stroma and blood vessels in uremia and CAPD patients.Adv Perit Dial1990; 6: 3–12.
53.
Di PaoloN., SacchiG.The peritoneum during peritoneal dialysis. In: Di PaoloN., SacchiG., eds. Atlas of peritoneal histology.Perit Dial Int2000; 20(Suppl 3): S37–63.
54.
DobbieJ.W., AndersonJ.D., HindC.Long-term effects of peritoneal dialysis on peritoneal morphology.Perit Dial Int1994; 14(Suppl 3): S16–20.
55.
DobbieJ.W.Pathogenesis of peritoneal fibrosing syndromes (sclerosing peritonitis) in peritoneal dialysis.Perit Dial Int1992; 12: 14–27.
56.
SuassunaJ.H.R., Das NevesF.C., HartleyB., OggC.S., CameronJ.S.Immunohistochemical studies of the peritoneal membrane and infiltrating cells in normal subjects and patients on CAPD.Kidney Int1994; 46: 443–54.
57.
DobbieJ.W.New concepts in molecular biology and ultrastructural pathology of the peritoneum: Their significance for peritoneal dialysis.Am J Kidney Dis1990; 15: 97–109.
58.
Ho-dac-PannekeetM.M., HiralallJ.K., StruijkD.G., KredietR.T.Longitudinal follow-up of CA125 in peritoneal effluent.Kidney Int1997; 51: 888–93.
59.
PannekeetM.M., KoomenG.C.M., StruijkD.G., KredietR.T.Dialysate CA125 in stable CAPD patients: No relation with transport parameters.Clin Nephrol1995; 44: 248–54.
60.
WongE.C.C.Difficulties in analysis of CA125 in diluted samples.Clin Chem1995; 41: 1543–4.
61.
SanusiA.A., ZweersM.M., WeeningJ.J., de WaartD.R., StruijkD.G., KredietR.T.Expression of cancer antigen 125 by peritoneal mesothelial cells is not influenced by duration of peritoneal dialysis.Perit Dial Int2001; 21: 495–500.
62.
LaiK.N., LaiK.B., SzetoC.C., HoK.K.L., PoonP., LamC.W.K.Dialysate cell population and cancer antigen 125 in stable continuous ambulatory peritoneal dialysis patients: Their relationship with transport parameters.Am J Kidney Dis1997; 29: 699–705.
63.
JimenezC., DiazC., SelgasR., BajoM.A., Del PesoG., Sánchez–TomeroJ.A.Peritoneal kinetics of cancer antigen 125 in peritoneal dialysis patients: The relationship with peritoneal outcome.Adv Perit Dial1999; 15: 36–9.
64.
KawanishiH., MoriishiM., HaradaY., SakikuboE., NagaiT., TsuchiyaS.Necessity of correcting cancer antigen 125 appearance rates by body surface area.Adv Perit Dial2000; 16: 22–5.
BoutsA.H.M., GroothoffJ.W., Ploos van AmstelS., ZweersM.M., DavinJ-C, KredietR.T.Dialysate cancer antigen 125 levels in children treated with peritoneal dialysis.Adv Perit Dial2000; 16: 328–31.
67.
FlessnerM.Osmotic barrier of the parietal peritoneum.Am J Physiol1994; 267: F861–70.
DoumaC.E., De WaartD.R., StruijkD.G., KredietR.T.The nitric oxide donor nitroprusside intraperitoneally affects peritoneal permeability in CAPD.Kidney Int1997; 51: 1885–92.
70.
Ho-dac-PannekeetM.M., KredietR.T.Inflammatory changes in vivo during CAPD: what can the effluent tell us?Kidney Int1966; 50(Suppl 56): S12–16.
71.
ZemelD., KoomenG.C.M., HartA.A.M., Ten BergeR.J.M., StruijkD.G., KredietR.T.Relationship of TNF-a, interleukin-6 and prostaglandins to peritoneal permeability for macromolecules during longitudinal follow-up of peritonitis in continuous ambulatory peritoneal dialysis.J Lab Clin Med1993; 122: 686–96.
72.
ZemelD., StruijkD.G., DinklaC., StolkL.M., Ten BergeR.J.M., KredietR.T.Effects of intraperitoneal cyclooxygenase inhibition on inflammatory mediators in dialysate and peritoneal membrane characteristics during peritonitis in continuous ambulatory peritoneal dialysis.J Lab Clin Med1995; 126: 204–15.
73.
ZemelD., KredietR.T.Cytokine patterns in the effluent of continuous ambulatory peritoneal dialysis: Relationship to peritoneal permeability.Blood Purif1996; 14: 198–216.
74.
FusshöllerA., GrabenseeB., PlumJ.CA125 in the effluent of chronic peritoneal dialysis (PD) patients: Relation to transport parameters, peritonitis, PD duration, and regime (Abstract).Perit Dial Int2000; 20(Suppl 1): S7.
75.
Hagmolen of ten Have W, Ho-dac-PannekeetM.M., StruijkD.G., KredietR.T.Mesothelial regeneration after peritonitis in dialysis patients (Abstract).J Am Soc Nephrol1997; 8: 180A.
76.
Ho-dac-PannekeetM.M., HiralallJ.K., StruijkD.G., KredietR.T.Markers of peritoneal mesothelial cells during treatment with peritoneal dialysis.Adv Perit Dial1997; 13: 72–6.
77.
IleriT., SöylemezogluO., SindelS., ÖzkayaO., DericiÜ, ArinsoyT.The predictive value of cancer antigen 125 (CA125), collagen III, plasminogen activator inhibitor type-1 (PAI-1), basic fibroblast growth factor (bFGF) on peritoneal fibrosis in chronic peritoneal dialysis (Abstract).Nephrol Dial Transplant2000; 15: A234.
78.
Ho-dac-PannekeetM.M.Assessment of peritoneal permeability and mesothelial cell mass in peritoneal dialysis patients (Thesis).Amsterdam: University of Amsterdam, 1997.
79.
BurkartJ., StallardR.Result of peritoneal membrane (PM) resting (R) on dialysate (d) CA125 levels and PET results (Abstract).Perit Dial Int1997; 17(Suppl 1): S5.
80.
MoriishiM., SakikuboE., AsakimoriY., KumagaiJ., SkintakuS., TsuchiyaS.CA125 appearance rate is useful marker for peritoneal sclerosis in long-term CAPD patients (Abstract).Perit Dial Int1998; 18(Suppl 2): S90.
81.
MirandaB., SelgasR., CeladillaO., MuñozJ., Sánchez–SiciliaL.Peritoneal resting and heparinization as an effective treatment for ultrafiltration failure in patients on CAPD.Contrib Nephrol1991; 89: 199–204.
82.
Da AlvaroF., CastroM.J., DapenaF., BajoM.A., Fernandez–ReyesM.J., RomeroJ.R.Peritoneal resting is beneficial in peritoneal hyperpermeability and ultrafiltration failure.Adv Perit Dial1993; 9: 56–61.
HebahN.Ultrafiltration failure (UFF) in long-term peritoneal dialysis (PD): A case report (Abstract).Perit Dial Int2000; 20: 127.
85.
KredietR.T.The peritoneal membrane in chronic peritoneal dialysis.Kidney Int1999; 55: 341–56.
86.
Ho-dac-PannekeetM.M.Peritoneal fluid markers of mesothelial cells and function.Adv Ren Replace Ther1998; 5: 205–11.
87.
SimonsenO., WieslanderA., LandgrenC., RippeB.Less infusion pain and elevated level of cancer antigen 125 by the use of a new and more biocompatible PD fluid.Adv Perit Dial1996; 12: 156–60.
88.
CappelliG., BandianiG., CancariniG.C., FerianiM., Dell'AquilaR., SaffiotiS.Low concentrations of glucose degradation products in peritoneal dialysis fluids and their impact on biocompatibility parameters: Prospective cross-over study with a three-compartment bag.Adv Perit Dial1999; 15: 238–42.
89.
RippeB., SimonsenO., HeimbürgerO., ChristenssonA., HaraldssonB., StelinG.Long-term clinical effects of a peritoneal dialysis fluid with less glucose degradation products.Kidney Int2001; 59: 348–57.
90.
JonesS., HolmesC.J., KredietR.T., MackenzieR., FaictD., TranæusA.Continuous dialysis with bicarbonate/lactate based peritoneal dialysis solution is associated with an increase in dialysate CA125 and a decrease in hyaluronic acid (HA) levels.Kidney Int2001; 59: 1529–38.
